Physician profile
Jason C Levine
NPI 1083749642
$13,496.13
in general payments reported to CMS, 2019-2025
37 companies · $1,802 in 2025
The $1,802 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,432 · 2020: $497 · 2021: $3,154 · 2022: $3,241 · 2023: $2,299 · 2024: $1,070 · 2025: $1,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,132 · Travel and Lodging: $23.00 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,131.67 |
| Travel and Lodging | $23.00 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $4,351.81 | 2020-2023 | Orsiro Mission |
| Abiomed | $1,112.03 | 2019-2025 | Impella |
| Amgen INC. | $647.79 | 2019-2025 | Repatha, Repatha |
| Cathworks, INC. | $574.50 | 2024-2025 | Ffrangio |
| Shockwave Medical, INC | $511.75 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Astrazeneca Pharmaceuticals Lp | $467.84 | 2019-2025 | Farxiga |
| Amarin Pharma, INC. | $455.30 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $408.35 | 2019-2024 | Xarelto |
| Abbott Laboratories | $398.87 | 2019-2024 | Aveir, Perclose Prostyle |
| Merck Sharp & Dohme LLC | $391.23 | 2022-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.48 | 2020-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $358.67 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $347.68 | 2019-2025 | Wegovy, Ozempic |
| Pfizer INC. | $331.64 | 2019-2025 | |
| Boston Scientific Corporation | $292.33 | 2020-2025 | General - Crm_crm, Watchman Access System, Watchman Flx |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $273.73 | 2021-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $248.32 | 2022-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $237.14 | 2019-2025 | |
| Chiesi USA, INC. | $220.92 | 2019 | |
| Cardiva Medical, INC. | $200.26 | 2025 | Optowire, Cardiva Vascade Mvp Xl Vvcs 10-12f, Savvywire |
| Medtronic, INC. | $193.74 | 2021-2023 | Corevalve Evolut R |
| Cardiovascular Systems INC. | $155.13 | 2019-2022 | |
| Medtronic Vascular, INC. | $132.07 | 2019-2020 | |
| Ets Wound Care LLC | $131.73 | 2024 | Mirragen Advanced Wound Matrix |
| Sanofi-Aventis U.S. LLC | $126.18 | 2019-2023 | |
| Scpharmaceuticals INC. | $105.56 | 2024-2025 | |
| Nuwellis, INC. | $87.54 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $86.37 | 2024-2025 | Onpattro |
| Lexicon Pharmaceuticals, INC. | $82.41 | 2023-2024 | Inpefa |
| Penumbra, INC. | $57.53 | 2022-2023 | Indigo System |
| Bayer Healthcare Pharmaceuticals INC. | $22.25 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $21.49 | 2019 | |
| Atricure, INC. | $21.10 | 2024 | |
| Preventice Services, LLC | $17.63 | 2021 | |
| Ge Healthcare | $16.73 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $13.80 | 2023 | Uptravi, Opsumit |
| Cvrx, INC. | $9.23 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.